Device Trial Radar · NCT01617954
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
Last checked: Nov 20, 2026Latest source record: Jan 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- AgendiaNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 13, 2012
Design
- Study type
- Observational
- Who can join
- Female only, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.
Conditions
- Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
MammaPrintDevice
All subjects
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in recommended adjuvant chemotherapy treatmentTime frame: 30 days
Locations
53 sites in 1 country. Site status is shown where the registry gives one.
Maricopa Integrated Health System
Phoenix, Arizona
52 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.